Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APOL1 | O14791 | 2/20 | 0.32 |
| ▸ | F12 | P00748 | 5/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3666639 | 0.75 | SLC2A1 (0.35) | APOL1F12 | |
| SCHEMBL23114086 | 0.70 | TAS1R3 (0.35) | — | |
| SCHEMBL23114088 | 0.70 | TAS1R3 (0.35) | — | |
| SCHEMBL23113976 | 0.67 | TAS1R3 (0.36) | — | |
| SCHEMBL23113973 | 0.67 | TAS1R3 (0.36) | — | |
| SCHEMBL19949276 | 0.67 | TAS1R3 (0.35) | — | |
| SCHEMBL1876773 | 0.67 | TAS1R3 (0.36) | — | |
| SCHEMBL22501502 | 0.67 | TAS1R3 (0.36) | — | |
| SCHEMBL19948687 | 0.66 | TAS1R3 (0.38) | — | |
| SCHEMBL18062656 | 0.65 | RAB9A (0.57) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2231668-A1 | CONDENSED PENTACYCLIC DERIVATIVES FOR USE IN THE TREATMENT OF FLAVIVIRIDAE INFECTIONS | GlaxoSmithKline LLC (US) | 2010-09-29 | — | — | EP | disclosed |
| US-20090197856-A1 | ANTIVIRAL COMPOUNDS | GENELABS TECHNOLOGIES, INC. | 2009-08-06 | — | — | US | disclosed |
| WO-2009086139-A1 | CONDENSED PENTACYCLIC DERIVATIVES FOR USE IN THE TREATMENT OF FLAVIVIRIDAE INFECTIONS | GENELABS TECHNOLOGIES, INC. (US) | 2009-07-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090197856-A1 | ANTIVIRAL COMPOUNDS | ZC3HAV1, EIF2AK2, MAVS | APOL1 844/4885F12 1075/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.